This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Valeo Pharma Valuation

Is VP2 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VP2 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VP2's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VP2's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for VP2?

Key metric: As VP2 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VP2. This is calculated by dividing VP2's market cap by their current revenue.
What is VP2's PS Ratio?
PS Ratio	0.01x
Sales	CA$53.38m
Market Cap	CA$727.02k

VP2 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.2x
Enterprise Value/EBITDA	-4.5x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does VP2's PS Ratio compare to its peers?

The above table shows the PS ratio for VP2 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	6.3x
B8FK Biofrontera	0.8x	n/a	€16.4m
SBH Sangui Biotech International	3.8x	n/a	€419.8k
SBX SynBiotic	7.2x	39.7%	€27.9m
0RX Redx Pharma	13.3x	-37.6%	€65.0m
VP2 Valeo Pharma	0.01x	20.9%	€493.4k

Price-To-Sales vs Peers: VP2 is good value based on its Price-To-Sales Ratio (0x) compared to the peer average (6.3x).

Price to Sales Ratio vs Industry

How does VP2's PS Ratio compare vs other companies in the European Pharmaceuticals Industry?

23 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	2.9x	3.4%
VP2 Valeo Pharma	0.01x	20.9%	US$520.38k

23 Companies		Estimated Growth	Market Cap
Industry Avg.	2.9x	21.6%
VP2 Valeo Pharma	0.01x	n/a	US$520.38k

No more companies

Price-To-Sales vs Industry: VP2 is good value based on its Price-To-Sales Ratio (0x) compared to the European Pharmaceuticals industry average (3.1x).

Price to Sales Ratio vs Fair Ratio

What is VP2's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VP2 PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.01x
Fair PS Ratio	14.6x

Price-To-Sales vs Fair Ratio: VP2 is good value based on its Price-To-Sales Ratio (0x) compared to the estimated Fair Price-To-Sales Ratio (14.6x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Aspen Pharmacare Holdings

R75.5b

Manufactures and supplies specialty and branded pharmaceutical products worldwide.

LDZA

R8.95

0.6%

4.7%

Amneal Pharmaceuticals

US$2.6b

Develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide.

2DT

US$7.70

-4.3%

91.5%

Almirall

€1.8b

A biopharmaceutical company, engages in the purchase, manufacture, storage, and sale of skin-health medicines in Europe, the Middle East, the United States, Asia, and Africa.

E2Z

€8.29

-1.8%

0.2%